Stamp, Lisa K. http://orcid.org/0000-0003-0138-2912
Farquhar, Hamish http://orcid.org/0000-0003-3060-4019
Pisaniello, Huai Leng
Vargas-Santos, Ana B. http://orcid.org/0000-0001-5307-0254
Fisher, Mark
Mount, David B. http://orcid.org/0000-0003-0310-2304
Choi, Hyon K.
Terkeltaub, Robert
Hill, Catherine L. http://orcid.org/0000-0001-8289-4922
Gaffo, Angelo L.
Article History
Accepted: 28 June 2021
First Online: 30 July 2021
Competing interests
: H.K.C. declares that he has received consulting fees from Takeda and Selecta (less than $10,000 each), research support from Horizon on an unrelated project, and is a member of the Data Safety Monitoring Committee for the VA-CSP 594 STOP GOUT clinical trial. R.T. declares that he has received consulting fees from AstraZeneca, Genentech, Horizon, SOBI (less than $10,000 each) and Selecta (more than $10,000). The other authors declare no competing interests. G-CAN is supported at arm’s length by unrestricted by grants from pharma companies including AstraZeneca, Horizon and LG within the past 12 months. No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.